Seattle Genetics, Roche deal

Seattle Genetics added antigens to a 2002 deal that gave Roche's Genentech Inc. unit rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology. Seattle Genetics will receive $12 million up front for the additional antigens, which will be chosen by Genentech. Genentech said it will focus on hematologic malignancies and solid tumors. ...